Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
- 1 May 2013
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (5), 1416-1418
- https://doi.org/10.1093/annonc/mdt074
Abstract
No abstract availableFunding Information
- National Cancer Research Institute
- Experimental Cancer Medicine Centre
This publication has 4 references indexed in Scilit:
- Dual Roles of PARP-1 Promote Cancer Growth and ProgressionCancer Discovery, 2012
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate CancerCancer Cell, 2011
- Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangementsNature Genetics, 2010
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersNew England Journal of Medicine, 2009